Our pipeline includes development programs that leverage our two platform technologies; one platform developed by our R&D scientists (OP-01) and the other obtained via a license acquisition in November 2015 (OP-02).
OP-01 is a novel, investigational pharmaceutical delivery platform that has the potential to overcome the major challenges of treating otolaryngology disorders. These challenges include insufficient coverage, drug residence time, the need for repeated and frequent administration and in cases of the external ear canal, the need to tilt the head sideways and remain lying down.
The first generation investigational product using this platform is Foam Otic Cipro, which has been evaluated in the clinic though phase 2 studies. It contains the same concentration of ciprofloxacin (0.3%), an antibiotic, as other approved otic drugs and is made only of a combination of inactive ingredients approved for otic and/or topical use.
The second generation investigational product using this platform is OP-0102. It contains ciprofloxacin, an antibiotic, and an anesthetic agent.
OP-02 is a novel, investigational pharmaceutical product that has the potential to treat conditions of the middle and inner ear by restoring function of the Eustachian tube (ET) and thereby preventing Otitis Media (inflammation of the middle ear) and related morbidities.
OP0201 is the first formulation to be evaluated in the clinic. It is comprised of two active ingredients, dipalmitoylphosphatidylcholine (DPPC [a phospholipid surfactant; also known as colfosceril palmitate]) and cholesteryl palmitate (CP [a neutral phospholipid spreading agent]). These surfactants are suspended in synthetic chlorofluorocarbon-free propellant, hydrofluoroalkane 134a (HFA-134a), which is an inactive substance.